Italy to Be First Beneficiary of EU Malaria Fund: Siena-Based Achilles Vaccines srl to Receive Financing to Fight Malaria and COVID-19
19.6.2020 10:37:00 EEST | Business Wire | Press release
The EU Malaria Fund (EUMF) yesterday presented its first investment into Achilles Vaccines srl at the premises of Fondazione Monte dei Paschi di Siena in Italy. The investment supports development of a novel Malaria vaccine on its versatile technology platform transforming bacteria, natural carriers of molecules harmful to human health, into an efficient delivery system of bio antigenic molecules to produce low-cost, safe and self-adjuvanting fit-for-purpose vaccines. The EUMF funding, with support from Fondazione TLS, will also be used to advance Achilles’ project to develop a novel human monoclonal antibody against COVID-19.
The first recipient of EUMF funding, Achilles, is a Siena-based biotech company specialising in research on malaria, antimicrobial resistance and, lately, COVID-19. “Achilles Vaccines is proud to contribute to the search for vaccines to eliminate malaria, a disease that faded into the background in these dramatic months, but which still claims significantly more victims than COVID-19 does, especially among children. Thanks to the guidance of Dr Rappuoli, we escape the challenge of finding a therapeutic and prophylactic drug with our monoclonal antibody, that finally makes the pandemic in which we find ourselves manageable”, said Riccardo Baccheschi, President and CEO of Achilles.
Holm Keller, Managing Director of EUMF and Chairman of kENUP Foundation said: “The EU Malaria Fund has high hopes, that the investment at the heart of the Siena vaccine hub in Italy will help to accelerate the eradication of Malaria. I am delighted that in these trying times, innovative Italian companies, like Achilles, will play a role in developing solutions against COVID-19".
The European Commission and the European Investment Bank (EIB) are investing €111 million into the fund. “Vaccines are important for disease prevention,” said Ambroise Fayolle, EIB Vice President in charge of innovation. “But often they also generate lower revenues than drugs and other health care services and are thus less attractive for private investors. This is why initiatives like the EU Malaria Fund are so important. We are glad to see the first investment of this Fund materialise so quickly and hope that it will allow AchilleS to progress in this important field of research.”
“We are very proud to be the first Italian foundation to invest in the EU Malaria Fund. With a 1 million euros amount, the Fondazione MPS is pursuing two main goals in a long-term vision: supporting scientific research for those diseases that have a big impact on public health and attracting financial resources with long-term benefits for the province of Siena. – said Carlo Rossi, Chairman of Fondazione Monte dei Paschi di Siena, “We also appreciate that the EU Malaria Fund will support the COVID-19 research, as it represents, at the moment, the most important worldwide sanitary challenge that requires huge common efforts”.
The EIB and WHO support the development of the EU Malaria Fund. “Together with WHO’s technical expertise we are confident of accelerating the development of new and innovative tools. The first investment of the EU Malaria Fund in Achilles will meaningfully advance the renewed efforts in our fight against Malaria” said Dr Pedro Alonso, Director of the World Health Organisation’s Global Malaria Programme.
The EUMF is a public-private partnership between the European Union, international organisations, corporations, and organized civic society, providing a novel funding instrument to address market failures in infectious diseases with significant relevance to public health globally. Further information can be found at www.controlMalaria.eu.
The video of the event can be found at https://www.controlmalaria.eu/news
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200619005083/en/
Contact information
Achilles Vaccines:
Eleonora Cossa
e.cossa@vrelations.it
+ 39 347.7467250
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 04:00:00 EEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe ’s Coverage of ESCMID Global Congress 202617.7.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 01:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-treat, high-impact sites, including the scalp, nails, palms and soles, compared with placebo.1-5 These data build on the topline results from the Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled LATITUDE PsO 3001 and 3002 studies.2,6 In those studies, about 70% of patients treated with zasocitinib achieved static Physician Global Assessment (sPGA) 0/1 (clear or almost clear skin) at week 16, with a significantly greater Psoriasis Area and Severity Index (PASI) 75 response rate seen as early as w
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance17.7.2026 00:36:00 EEST | Press release
The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful placement, Merz has further diversified its funding base by
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 23:22:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom